SIBN

SI-BONE Inc

Add to Watchlist

Advanced Chart

17.250

-0.11(-0.634%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

17.5452

Open

17.510

VWAP

17.31

Vol

208.80K

Mkt Cap

735.10M

Low

17.205

Amount

3.61M

EV/EBITDA(TTM)

Total Shares

41.20M

626.17M

EV/OCF(TTM)

P/S(TTM)

4.08

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

53.93M

+10.05%

-0.133

+20.45%

46.38M

+14.98%

-0.174

+8.59%

48.12M

+20.39%

-0.177

-19.32%

Estimates Revision

The market is revising Downward the revenue expectations for SI-BONE, Inc. (SIBN) for FY2025, with the revenue forecasts being adjusted by -0.18% over the past three months. During the same period, the stock price has changed by 19.21%.

Revenue Estimates for FY2025

Revise Downward

-0.18%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-5.91%

In Past 3 Month

Stock Price

Go Up

+19.21%

In Past 3 Month

7 Analyst Rating

40.81% Upside

Wall Street analysts forecast SIBN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SIBN is 24.29 USD with a low forecast of 19.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

40.81% Upside

Current: 17.250

Low

19.00

Averages

24.29

High

32.00

40.81% Upside

Current: 17.250

Low

19.00

Averages

24.29

High

32.00

Needham

David Saxon

Strong Buy

Reiterates

$19

2025-01-13

Reason

Needham

David Saxon

Price Target

$19

2025-01-13

Reiterates

Strong Buy

Reason

Needham

David Saxon

Strong Buy

Reiterates

$19

2024-11-20

Reason

Needham

David Saxon

Price Target

$19

2024-11-20

Reiterates

Strong Buy

Reason

Needham

David Saxon

Strong Buy

Reiterates

$19

2024-11-13

Reason

Needham

David Saxon

Price Target

$19

2024-11-13

Reiterates

Strong Buy

Reason

Truist Securities

Samuel Brodovsky

Strong Buy

Maintains

$16 → $18

2024-11-13

Reason

Truist Securities

Samuel Brodovsky

Price Target

$16 → $18

2024-11-13

Maintains

Strong Buy

Reason

Truist Securities

Samuel Brodovsky

Strong Buy

Maintains

$18 → $16

2024-10-14

Reason

Truist Securities

Samuel Brodovsky

Price Target

$18 → $16

2024-10-14

Maintains

Strong Buy

Reason

Needham

David Saxon

Strong Buy

Maintains

$27 → $19

2024-08-06

Reason

Needham

David Saxon

Price Target

$27 → $19

2024-08-06

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for SI-BONE Inc (SIBN.O) is -27.39, compared to its 5-year average forward P/E of -17.04. For a more detailed relative valuation and DCF analysis to assess SI-BONE Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.04

Current PE

-27.39

Overvalued PE

-11.98

Undervalued PE

-22.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

44.32

Current EV/EBITDA

125.95

Overvalued EV/EBITDA

385.67

Undervalued EV/EBITDA

-297.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.82

Current PS

3.73

Overvalued PS

8.24

Undervalued PS

3.40